Developing a new medication can cost over $1 billion, depending on the drug’s complexity and expenses accrued via unsuccessful studies. Considering these costs, an optimized regulatory process is ...
SARASOTA, FL, July 18, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and ...
Industry experts shared their insights and expertise on overcoming the most pressing Chemistry, Manufacturing, and Controls (CMC) challenges at LSX Biopharm America on September 11. This article ...
Safety and efficacy of two candidates are currently being assessed in investigator-initiated clinical trials. BRC is planning to commence enrollment for Phase 2 and 3 trials by mid 2026. MONTEREY, ...
Clinical efficacy top-line results of PARADIGM, a Phase 2b trial in ALS, expected in December 2023 CAMBRIDGE, Mass., Nov. 13, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NRSN) ("NeuroSense"), a ...
iECURE, Inc., a clinical-stage genome editing company developing variant-agnostic in vivo targeted gene insertion therapies for the treatment of severe, inherited, neurometabolic disorders, today ...
The market opportunity lies in offering specialized training and consultancy services to pharmaceutical companies for navigating complex CMC regulatory requirements for biological drugs, ensuring ...
Breakthrough Therapy designation based on interim clinical data from Phase I/II trials showing clinically meaningful improvements in cardiac biomarkers and functional measures LX2006 also selected for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results